Proc. roy. Soc. Med. Volume 63 June 1970 26 to five years; so that by then 13, or 60%, remained. Since then only one more patient has diedafter thirteen yearsand the proportions of those alive at ten years and at fifteen years were the same as at five years. All 3 patients with adenomas were alive at five years, while all 4 with carcinomas were dead in one year. Three of the 4 with pituitary tumours initially were dead in three years. The fourth was in remission and well after ten years.
This, then, is our experience of the natural history of treated Cushing's syndrome. Clearly, the first year after operation is the most hazardous. Thereafter those who survive the first five years have an excellent chance of surviving fifteen years and of leading normal lives.
Dr D A D Montgomery (The Sir George E Clark Metabolic Clinic, Royal Victoria Hospital, Belfast BT12 6BA) said he felt that subtotal adrenalectomy still had a part to play in the treatment of certain cases of Cushing's syndrome due to adrenal hyperplasia, especially if effective follow up could be maintained. While agreeing that the adrenal remnant in such cases often functioned subnormally he thought that in others adrenal function returned to normal and he instanced the case of one young woman who had had a subtotal adrenalectomy sixteen years ago and whose initial subnormal response had now become normal.
Such cases might fall into the category of patients with Cushing's syndrome without pituitary tumours or other structural abnormality in the hypothalamic-pituitary region, whose adrenal hyperplasia possibly resulted from a functional disturbance of the hypothalamicpituitary axis. If so, subtotal adrenalectomy might be an excellent method of treatment, but unfortunately there was no means as yet of detecting such patients during life. Finally, total adrenalectomy was important for control of the features of Cushing's syndrome in those patients with suspected pituitary lesions such as those with full-sized pituitary fosse, but without sufficient evidence to make a definitive diagnosis of pituitary tumour. It is just ten years since Hazard et al. 1959 first described medullary carcinoma of the thyroid as a distinct entity. Williams (1967) added considerably to our knowledge of this tumour. The medullary carcinoma is a solid tumour composed of islands or nests of polygonal cells with clear or eosinophilic granular cytoplasm. A constant feature is the presence of amyloid in variable amounts in the stroma. The tumour, which is slow growing, is derived from parafollicular (C) cells which normally secrete calcitonin, and large quantities of calcitonin have now been found in tumours and in the plasma of patients with medullary carcinoma (Cunliffe et al. 1968 ). Davis (1967) reported that the incidence of medullary carcinoma in a series of 222 patients was 6-8 % and similar incidence has been reported by others.
The histological material from all patients with malignant disease of the thyroid, seen in the Royal Victoria Infirmary since 1960, was examined. The distribution of tumour types is shown in Table 1 . Five patients (7%Y.) were found to have medullary carcinoma. A review of these 5 patients revealed some of the clinical and histological characteristics of this tumour and serum calcitonin levels were measured in 3. The main features of this group of patients are given in Table 2 . 
